D
셀레스트라
352770KOSDAQ의료용품 및 기타 의약 관련제품 제조업39.5 / 100
Reference Date: 2026-04-13
Financial Score10.0 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure7.0 / 15
AI Analysis: the high debt ratio poses financial risk, Revenue is on a declining trend. Roughly flat over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Celestera develops and commercializes services for early disease diagnosis using genome-based biohealth information processing, liquid biopsy platforms, cancer diagnostics, and multi-omics technologies. Key products include Geno-Test, CD-Prime, and Cancer-Prime, with a dedicated bio big data center for research and commercialization.
Number of Employees
11people
Average Salary
85.7M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 13.514.0Point
PBR
2.48Industry Average 2.142.5Point
Higher than industry avg (caution)
ROE
-211.60Industry Average -3.613.5Point
58.6x industry avg (excellent)
Debt Ratio
877.67Industry Average 50.270.0Point
17.5x industry avg (risky)
Trend 2022~20240.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼38.0% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼101.9% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -151.8% (declining, 2yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position4.0Point
52w mid range (50%)
Current 5,250Won52-week high 5,25052-week low 5,250
1-month return3.0Point
1m 0% (flat)
Volume trend3.0Point
Volume flat
Detailed Disclosure
7 totalPositive 0Neutral 6Negative 1
- Neutral사업보고서 (2025.12)2026-04-07
- Neutral감사보고서제출2026-04-07
- Neutral주권매매거래정지기간변경 (상장폐지 사유 발생)2026-04-07
- Neutral기타시장안내 (상장폐지 관련)2026-04-07
- Neutral기타경영사항(자율공시) (감사보고서 제출 지연)2026-03-24